SG Americas Securities LLC lowered its holdings in Precigen, Inc. (NASDAQ:PGEN – Get Rating) by 41.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,326 shares of the biotechnology company’s stock after selling 24,633 shares during the period. SG Americas Securities LLC’s holdings in Precigen were worth $54,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in PGEN. Inspire Advisors LLC grew its holdings in Precigen by 21.8% in the fourth quarter. Inspire Advisors LLC now owns 47,079 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 8,435 shares during the period. Strs Ohio purchased a new stake in shares of Precigen during the fourth quarter worth about $76,000. Chiron Capital Management LLC lifted its stake in shares of Precigen by 50.2% in the fourth quarter. Chiron Capital Management LLC now owns 69,498 shares of the biotechnology company’s stock worth $106,000 after acquiring an additional 23,222 shares in the last quarter. Pendal Group Ltd purchased a new position in Precigen in the fourth quarter valued at about $151,000. Finally, Bank of New York Mellon Corp grew its stake in Precigen by 6.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 336,337 shares of the biotechnology company’s stock valued at $713,000 after purchasing an additional 21,839 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Precigen in a research note on Tuesday, March 7th. Cantor Fitzgerald boosted their target price on shares of Precigen from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Monday, January 30th. JMP Securities restated a “buy” rating and issued a $14.00 target price on shares of Precigen in a research note on Tuesday, March 7th. Finally, StockNews.com started coverage on Precigen in a research note on Thursday, March 16th. They issued a “sell” rating for the company.
Precigen Stock Up 1.6 %
Precigen Company Profile
Precigen, Inc is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
- Get a free copy of the StockNews.com research report on Precigen (PGEN)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Want to see what other hedge funds are holding PGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Precigen, Inc. (NASDAQ:PGEN – Get Rating).
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.